Suppr超能文献

富碘草药治疗Graves病甲亢的疗效:一项单中心回顾性队列研究

Therapeutic effectiveness of iodine-rich herbs in treating Graves' hyperthyroidism: a retrospective cohort study from a single center.

作者信息

Lai Yiwen, Yang Mengfei, Li Jing, Gan Di, Liu Qingyang, Wang Yingna, Gao Tianshu

机构信息

Department of Endocrinology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.

Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.

出版信息

Front Endocrinol (Lausanne). 2025 Aug 11;16:1573617. doi: 10.3389/fendo.2025.1573617. eCollection 2025.

Abstract

OBJECTIVE

To evaluate the effectiveness of the traditional Chinese medicine decoction with iodine-rich herbs as the main agent (IRH) in patients with Graves' hyperthyroidism (GD).

METHODS

A retrospective cohort study was conducted in a tertiary A traditional Chinese medicine hospital in northeastern China. We followed the effectiveness and safety of IRH in treating GD patients from January 2010 to August 2024 through the Intelligent Research Data Platform. Patients treated with IRH were classified into the IRH cohort, and those treated with antithyroid drugs (ATD) were classified into the ATD cohort. The characteristics of the two groups were balanced using propensity score matching (PSM). We used logistic regression, the Kaplan-Meier method, and the Cox proportional hazard model to compare the efficacy differences between IRH and ATD and to preliminarily identify the influencing factors of IRH efficacy through subgroup analysis of clinical characteristics.

RESULTS

After screening and PSM, 73 GD patients treated with IRH and 73 with ATD were included in this study. IRH could significantly improve serum free T3 (fT3), free T4 (fT4), thyroid-stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels in GD patients. Among the 73 patients who received IRH, the serum fT3, fT4, and TSH levels of 63 (86.3%), 65 (89%), and 40 (54.8%) patients, respectively, returned to normal, and the efficacy of IRH persisted for 50 (68.5%) patients. In addition, the median time to normalization and the regression analysis after correction for confounding factors did not show significant differences between IRH and ATD regarding efficacy and persistence. The safety evaluation results of the two drugs were similar. Higher IRH doses (>= 40g) may improve efficacy, while younger age, male gender, goiter, and more severe thyrotoxicosis might lead to poor efficacy of IRH.

CONCLUSION

Compared with ATD, IRH could also significantly improve the serum fT3, fT4, TSH, and TRAb levels of patients with GD and has a comparable duration of efficacy. For patients with mild to moderate GD, IRH provided a safe as well as effective alternative therapy.

摘要

目的

评估以富碘中药为主的中药汤剂(IRH)治疗Graves病(GD)患者的疗效。

方法

在中国东北一家三级甲等中医医院进行一项回顾性队列研究。通过智能研究数据平台,我们追踪了2010年1月至2024年8月期间IRH治疗GD患者的有效性和安全性。接受IRH治疗的患者被分为IRH队列,接受抗甲状腺药物(ATD)治疗的患者被分为ATD队列。使用倾向评分匹配(PSM)使两组的特征达到平衡。我们使用逻辑回归、Kaplan-Meier法和Cox比例风险模型比较IRH和ATD之间的疗效差异,并通过临床特征亚组分析初步确定影响IRH疗效的因素。

结果

经过筛选和PSM,本研究纳入了73例接受IRH治疗的GD患者和73例接受ATD治疗的患者。IRH可显著改善GD患者的血清游离T3(fT3)、游离T4(fT4)、促甲状腺激素(TSH)和促甲状腺激素受体抗体(TRAb)水平。在73例接受IRH治疗的患者中,血清fT3、fT4和TSH水平分别有63例(86.3%)、65例(89%)和40例(54.8%)恢复正常,IRH的疗效在50例(68.5%)患者中持续存在。此外,校正混杂因素后的归一化中位时间和回归分析在疗效和持续性方面未显示IRH和ATD之间存在显著差异。两种药物的安全性评估结果相似。较高的IRH剂量(>=40g)可能会提高疗效,而年龄较小、男性、甲状腺肿和甲状腺毒症更严重可能导致IRH疗效不佳。

结论

与ATD相比,IRH也可显著改善GD患者的血清fT3、fT4、TSH和TRAb水平,且疗效持续时间相当。对于轻至中度GD患者,IRH提供了一种安全有效的替代疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a2e/12375487/0f2d756de06c/fendo-16-1573617-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验